For the quarter ending 2025-09-30, CYCN had $1,562K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2024-12-31 |
|---|---|---|---|
| Net loss | -976 | -1,753 | -3,057 |
| Gain on disposal of discontinued operations | - | - | 0 |
| Gain from settlement of account payable | 0 | - | 363 |
| Impairment loss | - | - | 0 |
| Share-based compensation expense | 118 | 228 | 625 |
| Accounts receivable | -425 | -31 | 556 |
| Prepaid expenses | -76 | 41 | -21 |
| Other current assets | -16 | 11 | 5 |
| Operating lease assets | - | - | 0 |
| Other assets | - | - | 0 |
| Accounts payable | 18 | 72 | -445 |
| Accrued research and development costs | -26 | 20 | -38 |
| Accrued expenses and other current liabilities | 85 | -17 | -515 |
| Net cash used in operating activities | -264 | -1,471 | -4,333 |
| Net proceeds from disposal of discontinued operations | - | - | 0 |
| Net cash provided by investing activities | - | - | 0 |
| Proceeds from atm | 1,826 | - | - |
| Proceeds from private placement | 0 | 1,375 | 0 |
| Proceeds from exercises of stock options and espp | - | - | 0 |
| Issuance costs paid for private placement | 0 | -130 | - |
| Net cash provided by financing activities | 1,826 | 1,245 | 0 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0 | -6 |
| Net increase (decrease) in cash and cash equivalents | 1,562 | -226 | -4,339 |
| Cash and cash equivalents at beginning of period | 3,232 | - | 7,571 |
| Cash and cash equivalents at end of period | 4,568 | - | 3,232 |
Cyclerion Therapeutics, Inc. (CYCN)
Cyclerion Therapeutics, Inc. (CYCN)